Instituto do Cancer de Sao Paulo - ICESP (Site 0211)

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Triple-negative breast cancer

Closed trials

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

  NCT03036488· Phase 3· Merck Sharp & Dohme LLC· Source